<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915837</url>
  </required_header>
  <id_info>
    <org_study_id>SRDX- 001</org_study_id>
    <nct_id>NCT00915837</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema</brief_title>
  <acronym>STRIDE</acronym>
  <official_title>Phase 1 Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SurModics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SurModics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will evaluate the safety, tolerability and duration of effect of a helical&#xD;
      intravitreal triamcinolone implant for the treatment of diabetic macular edema over a&#xD;
      three-year period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Helical Intravitreal Triamcinolone Implant is intended to provide sustained release of&#xD;
      triamcinolone acetonide into the vitreous chamber of the eye.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>every 3 months for 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCT</measure>
    <time_frame>every 3 months for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
    <time_frame>every 3 months for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit lamp exam/funduscopy</measure>
    <time_frame>every 3 months for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescein angiography</measure>
    <time_frame>every 3 months for 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>every 3 months for 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Slow release formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow release formulation, helical intravitreal triamcinolone implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fast release formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fast release formulation, helical intravitreal triamcinolone implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day</description>
    <arm_group_label>Slow release formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triamcinolone acetonide</intervention_name>
    <description>Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day</description>
    <arm_group_label>fast release formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically observable macular edema associated with diabetic retinopathy&#xD;
             in study eye&#xD;
&#xD;
          -  Macular edema in study eye is associated with&#xD;
&#xD;
               1. visual acuity of 20/40 or worse; and&#xD;
&#xD;
               2. retinal thickening in the fovea as seen on biomicroscopic examination&#xD;
&#xD;
               3. angiographic evidence of leakage involving the perifoveal capillary net&#xD;
&#xD;
          -  Failure of macular edema to improve with prior macular photocoagulation, or the&#xD;
             patient is unlikely to benefit from macular photocoagulation in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  Patients must be 18 years of age and older&#xD;
&#xD;
          -  Patients must be willing and able to return for scheduled follow up examinations for 3&#xD;
             years after initial surgery.&#xD;
&#xD;
          -  Patients must sign and be given a copy of the written Informed Consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Monocular, or vision worse than 20/400 in the fellow eye&#xD;
&#xD;
          -  Visual acuity worse than 20/200 20/200 and &lt; 34 letters read in the study eye&#xD;
&#xD;
          -  Use of depot periocular steroids in the study eye within the past 30 days&#xD;
&#xD;
          -  Current use of &gt;15 mg/day of oral steroids&#xD;
&#xD;
          -  Known steroid responder&#xD;
&#xD;
          -  Ocular hypertension &gt; 22 mmHg in the study eye or need for more than one medication to&#xD;
             maintain IOP &lt; 22 mmHg.&#xD;
&#xD;
          -  Cup to disc ratio of &gt; 0.8 in the study eye&#xD;
&#xD;
          -  Prior filtration surgery or glaucoma implant surgery in the study eye&#xD;
&#xD;
          -  Any active ocular infection in either eye&#xD;
&#xD;
          -  History of herpetic ocular infection in the study eye&#xD;
&#xD;
          -  Macular ischemia, defined as angiographic evidence of enlargement of the foveal&#xD;
             avascular zone to 1 disc area or larger, centered on the fovea&#xD;
&#xD;
          -  Macular or panretinal photocoagulation treatment in the study eye within the past 90&#xD;
             days; laser capsulotomy within the past 90 days&#xD;
&#xD;
          -  Planned or known need for ocular surgery in the study eye within 90 days after&#xD;
             enrollment and treatment&#xD;
&#xD;
          -  Any condition that precludes the subject's ability to comply with study requirements,&#xD;
             including examinations or the completion of the study; or any condition that precludes&#xD;
             the examiner's ability to obtain reliable fundus photography, angiography, or OCT&#xD;
             images&#xD;
&#xD;
          -  Females who are pregnant or lactating, and premenopausal females who are unwilling to&#xD;
             use a medically accepted method of birth control for the duration of the study&#xD;
&#xD;
          -  Participation in another investigational trial within 30 days prior to enrollment or&#xD;
             during the study period&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP &gt; 160 mm Hg and/or diastolic BP &gt; 90 mmHg)&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c &gt; 13)&#xD;
&#xD;
          -  Chronic renal failure requiring dialysis or anticipated renal transplant&#xD;
&#xD;
          -  Retinal or choroidal neovascularization in the study eye; anticipated need for&#xD;
             panretinal photocoagulation within the next 30 days&#xD;
&#xD;
          -  Macular edema in the study eye known to be due to a cause other than diabetic&#xD;
             retinopathy&#xD;
&#xD;
          -  Use of immunosuppressant drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert L Cantrill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VitreoRetinal Surgery, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pravin U Dugel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retinal Consultants of Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamer H Mahmoud, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kresege Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert L Avery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Retinal Consultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresege Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VitreoRetinal Surgery, PA</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shawn Fuller/ Director-Regulatory, Clinical &amp; Quality Compliance</name_title>
    <organization>SurModics, Inc.</organization>
  </responsible_party>
  <keyword>DME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

